115 related articles for article (PubMed ID: 19550250)
1. Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
Benedetti G; Latini L; Galetta D; Colucci G; Crinò L
J Thorac Oncol; 2009 Jul; 4(7):936-7. PubMed ID: 19550250
[No Abstract] [Full Text] [Related]
2. First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Le Maignan L; Mirebeau-Prunier D; Vervueren L; Jeanfaivre T; Urban T; Hureaux J
J Thorac Oncol; 2011 Mar; 6(3):639-40. PubMed ID: 21317745
[No Abstract] [Full Text] [Related]
3. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Weber B; Winterdahl M; Memon A; Sorensen BS; Keiding S; Sorensen L; Nexo E; Meldgaard P
J Thorac Oncol; 2011 Jul; 6(7):1287-9. PubMed ID: 21847041
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
5. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Pennell NA; Yin L; Keshtgarpour M; Ma PC
J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
[No Abstract] [Full Text] [Related]
6. Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
Kobayashi T; Takeda M; Marumo S; Koshimo Y; Teranishi T; Higami Y; Kato M
Lung Cancer; 2013 Apr; 80(1):109-11. PubMed ID: 23279871
[No Abstract] [Full Text] [Related]
7. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
Hata A; Kaji R; Fujita S; Katakami N
J Thorac Oncol; 2011 Mar; 6(3):653-4. PubMed ID: 21317753
[No Abstract] [Full Text] [Related]
8. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
De Pas T; Toffalorio F; Manzotti M; Fumagalli C; Spitaleri G; Catania C; Delmonte A; Giovannini M; Spaggiari L; de Braud F; Barberis M
J Thorac Oncol; 2011 Nov; 6(11):1895-901. PubMed ID: 21841502
[TBL] [Abstract][Full Text] [Related]
9. Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.
Weber B; Sorensen BS; Knap MM; Madsen HH; Nexo E; Meldgaard P
J Thorac Oncol; 2011 Nov; 6(11):1946-9. PubMed ID: 22005472
[TBL] [Abstract][Full Text] [Related]
10. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
[TBL] [Abstract][Full Text] [Related]
11. Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer.
Lanuti M; Sequist LV; Sharma A; Mino-Kenudson M
N Engl J Med; 2011 Oct; 365(15):1426-35. PubMed ID: 21995391
[No Abstract] [Full Text] [Related]
12. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Song Z; Zhang Y
J Clin Neurosci; 2014 Apr; 21(4):591-5. PubMed ID: 24256883
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.
De Pas T; Spitaleri G; Pelosi G; De Carlis L; Lorizzo K; Locatelli M; Curigliano G; Toffalorio F; Catania C; de Braud F
J Thorac Oncol; 2009 Jan; 4(1):138-9. PubMed ID: 19096323
[No Abstract] [Full Text] [Related]
16. Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
Chang JW; Chou CL; Huang SF; Wang HM; Hsieh JJ; Hsu T; Cheung YC
Lung Cancer; 2007 Dec; 58(3):414-7. PubMed ID: 17618013
[TBL] [Abstract][Full Text] [Related]
17. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
Molina-Vila MA; Bertran-Alamillo J; Reguart N; Taron M; Castellà E; Llatjós M; Costa C; Mayo C; Pradas A; Queralt C; Botia M; Pérez-Cano M; Carrasco E; Tomàs M; Mate JL; Moran T; Rosell R
J Thorac Oncol; 2008 Nov; 3(11):1224-35. PubMed ID: 18978556
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
[TBL] [Abstract][Full Text] [Related]
19. Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
Chonan M; Narita N; Tominaga T
BMC Res Notes; 2016 Jan; 9():2. PubMed ID: 26724810
[TBL] [Abstract][Full Text] [Related]
20. EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib.
Winther Larsen A; Nissen PH; Meldgaard P; Weber B; Sorensen BS
Lung Cancer; 2014 Sep; 85(3):435-41. PubMed ID: 25017413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
